MannKind reported $101.9M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Adma Biologics USD 124.4M 9.9M Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Insmed USD 524.42M 98.93M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
MacroGenics USD 32.83M 12.03M Jun/2026
MannKind USD 101.9M 7.47M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 147.14M 76.69M Dec/2025
Novo Nordisk DKK 12.13B 84.69B Jun/2026
Pfizer USD 16.6B 1.57B Sep/2026
Sanofi EUR 14.44B 2.49B Sep/2026
Xencor USD 116.52M 65.3M Sep/2026